Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer (Q33901988)
scientific article published on May 16, 2011
Language:
(P31) (Q13442814)
(P50) (Q73567269)
(P304) 2582-2589
(P407) (Q1860)
(P433) 18
(P478) 29
(P577) Monday, May 16, 2011
(P921) (Q42824440)
(Q269829)
(Q47912)
(Q418369)
(P953) https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.30.7678?role=tab
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.30.7678
(P1433) (Q400292)
(P1476) "Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer" (language: en)
"Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer" (language: en)
(P2093) Jeffrey Zangmeister
David R. Spigel
Howard A. Burris
F. Anthony Greco
Dianna L. Shipley
Elke K. Friedman
David M. Waterhouse
Robert C. Whorf
R. Brian Mitchell
Davey B. Daniel
J. David Bass
(P2860) (Q29547625)
(Q29547546)
(Q28296761)
(Q29617585)
(Q28282767)
(Q27861075)
(Q43299264)
(Q80798279)
(Q62991859)
(Q46209282)
(Q43098017)
(Q27860904)
(Q25938997)
(Q34935734)
(Q28278736)
(Q43138109)
(Q36519458)
(Q37633813)
(Q46068556)
other details
description scientific article published on May 16, 2011

External Links